US 6,982,075 B2 | ||
Use of pulmonary surfactant | ||
Friedemann Taut, Constance (Germany) | ||
Assigned to Altana Pharma AG, Constance (Germany) | ||
Appl. No. 10/491,961 PCT Filed Oct. 10, 2002, PCT No. PCT/EP02/11325 § 371(c)(1), (2), (4) Date Apr. 08, 2004, PCT Pub. No. WO03/033014, PCT Pub. Date Apr. 24, 2003. |
||
Claims priority of application No. 01000531 (EP), filed on Oct. 11, 2001. | ||
Prior Publication US 2004/0247529 A1, Dec. 09, 2004 | ||
Int. Cl. A61L 9/04 (2006.01) |
U.S. Cl. 424—45 | 3 Claims |
1. A method of treating a patient comprising administering a therapeutically effective amount of a pulmonary surfactant preparation
to a patient in order to decrease a risk or side effect of toxic oxygen concentration, wherein the patient is artificially
respirated and has a quotient of arterial oxygen partial pressure and inspiratory oxygen concentration (PaO2/FiO2) of 200
mmHg or lower, and
wherein the oxygen concentration of the gas employed for respiration is greater than or equal to 50% by volume.
|